


Figure 3

## How genomic profiling fits into the flow of information in the perioperative interval



## Figure 4 Allele Panel

Gene	Polymorphism	Incidence	Complication	Contra-indicated intervention	Indicated
BChE	A209G G1615A	0.05%/4% * ("atypical allele") 1.3%/22% * ("K-	prolonged apnea with succinylcholine	succinylcholine, mivacurium	use intermediate duration non-depolarizing muscle
CYP2D6	G1934A deletion A263 deletion T1795 deletion	66%** 17%** 4%**	inadequate analgesia with codeine; antiarryhthmic; and tricyclic antidepressant	omit codeine	relaxants use NSAIDs, other opioids; monitor plasma levels for drug toxicity; adjust dose, take drug interaction
MTHFR MS (MTR) MTRR CBS	C677T A1298C A2756G A66G Intron 7 68bp insertion	12%/>30%* new, not known with precision 2%/35%* 29%****	elevated blood homocysteine levels; thrombosis	nitrous oxide	precautions avoid nitrous oxide; take thrombosis precautions
FVL Prothrombin	G1691A G20210A	6% <b>***</b> *	hyper-coagulable state	If known in advance, avoid prolonged immobilization.	take thrombosis precautions
RYR1 CACNA1S	G6502A G1021A C1840T C6487T G7303A C7373A	7%*** 6-10%*** 4%*** 4%*** 4%*** 4 families	dysrhythmia, rigidity, renal failure, DIC (disseminated intravascular coagulation), death	succinylcholine; volatile anesthetic agents	use nitrous oxide and non-depolarizing muscle relaxants
ΤΝF-α ΤΝF-β	G-308A G+252A	16%****	exaggerated inflammatory response	No specific contra- indication	tailor immune modulation; detect inflammatory complications early; watch for infection

homozygote/heterozygote of poor metabolizers of manifesting phenotypes allele frequency . : : :

## Comparison of INVADER Assay with PCR-RFLP for Detection of Allelic Variants Figure 5

Drug Metabolism       Monoplex         BCHE G1615A, K variant       butyrtcholinesterase       Monoplex         BCHE A209G, Atypical       cytochrome P450 2D6       Biplex         CYP2D6*3       cytochrome P450 2D6       Biplex         Biplex       Biplex         CYP2D6*5       Biplex         CYP2D6*5       Biplex         CYP2D6*5       Biplex         CYP2D6*5       Monoplex         CYP2D6*5       Monoplex         FVL G1691A       Factor II         Homocycteine Level       Monoplex         MTHFR C677T       Monoplex         MTHFR C677T       Monoplex         MTR (MS) A2756G       methionine synthase       Monoplex         MTR (MS) A2756G       methioninie synthase       Monoplex         Inflammation       tumor necrosis factor alpha       Monoplex         TNFalpha – 308       tumor necrosis factor beta       Monoplex         TNFbeta +252       tumor necrosis factor beta       Monoplex			
5A, K variant the Solution of Atypical solution in East 198C 2756G 108 108 108 108 108 108 108 108 108 108	N. C.	:	!
G, Atypical  FII G20210A  ine Level  7T  2756G  2756G  nn  308	Monoplex	0	145
FII G20210A ine Level 7T 98C 2756G	Monoplex	0	164
FILG20210A FILG20210A 7T 98C 2756G 308 52	36 Biplex	0	168
FII G20210A ine Level 7T 98C 2756G	Biplex	က က	164
FI G20210A FI G20210A 7T 98C 2756G	Biplex	not done	176
5 FII G20210A ine Level 7T 98C 2756G 308 52	Biplex	0	163
II G20210A Ie Level T 3C 756G	the second secon		
II G20210A  E Level  T  3C  756G	Monoplex		132
e Level T 3C 756G	Monoplex	0	140
756G	emperature and the second seco		
3C 756G	late reductase Monoplex	0	145
756G 8	Monoplex	0	150
756G 8		0	158
8	Monoplex	0	147
8	e reductase Monoplex	2	150
	a de la compania del la compania de la compania del compania de la compania del compania de la compania de la compania de la compania de la c		
	or alpha Monoplex	2	163
	or beta Monoplex	0	163
Total (excluding 2D6*5)		8	2152
		1	%69.63%